We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Vir Biotechnology Inc
43 own
13 watching
Current Price
$7.63
$-0.41
(-5.1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,180.41M
52-Week High
27.48000
52-Week Low
7.61000
Average Volume
0.87M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,180.41M52-Week High27.4800052-Week Low7.61000Average Volume0.87MDividend Yield--P/E Ratio--What does the Vir Biotechnology Inc do?
Vir Biotechnology Inc is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and cause hundreds of billions of dollars of economic burden each year. Current development pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. VIR-2218, an HBV-targeting siRNA, is in an ongoing Phase 1/2 clinical trial and initial data have demonstrated substantial reduction of hepatitis B virus surface antigen, or HBsAg. Based on initial data, VIR-2218 has been generally well-tolerated.
Read More
How much money does Vir Biotechnology Inc make?
News & Events about Vir Biotechnology Inc.
Globe Newswire
10 months ago
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Companys strategic ...
Ticker Report
10 months ago
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 9,902 shares of the firms stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $25.18, for a total transaction of $249,332.36. Following ...
PR Newswire
10 months ago
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL Congress 2023 Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL Congress 2023 PR Newswire DURHAM, N.C. and BEIJING, June 25, 2023 Late-breaking data from...
Globe Newswire
10 months ago
Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or ...
Ticker Report
12 months ago
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) has been given a consensus rating of Moderate Buy by the eight analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating...
Frequently Asked Questions
Frequently Asked Questions
What is Vir Biotechnology Inc share price today?
Can Indians buy Vir Biotechnology Inc shares?
How can I buy Vir Biotechnology Inc shares from India?
Can Fractional shares of Vir Biotechnology Inc be purchased?
What are the documents required to start investing in Vir Biotechnology Inc stocks?
What is today’s traded volume of Vir Biotechnology Inc?
What is today’s market capitalisation of Vir Biotechnology Inc?
What is the 52-Week High and Low Range of Vir Biotechnology Inc?
What percentage is Vir Biotechnology Inc down from its 52-Week High?
What percentage is Vir Biotechnology Inc up from its 52-Week Low?
Current Price
$7.63
$-0.41
(-5.1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.